179324-69-7 Bortezomib N-pyrazinoyl-L-phenylalanine-L-boronoleucine
NLT 99.5% HPLC
COA,NMR,HPLC,MSDS, ROS, DMF all available.
We are offering three key services for new drug application,
a. Mature(repeatable) pilot process with independent intellectual property rights;
b. High purity sample designed for pharm companies;
c. Impurity study.
From Wikipedia, the free encyclopedia,
Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View